Company Overview and News
KUALA LUMPUR, April 13 — Bursa Malaysia bucked the regional trend to close easier today with the key index snapping its six-day winning streak, weighed by selling in index-linked counters led by MISC, Petronas Chemicals and Astro.
KUALA LUMPUR, April 13 — Bursa Malaysia opened lower this morning, reversing yesterday’s gains, and dampened by profit taking ahead of the weekend.
KUALA LUMPUR: Bio Osmo Bhd , Kerjaya Prospek Group Bhd , Dolphin International Bhd , Malakoff Corp Bhd, MMS Venture Bhd and Rex Industry Bhd are among the stocks to watch, according to JF Apex Research.
PETALING JAYA: Loss-making bottled drinking water company Bio Osmo Bhd plans to buy Impiana Group’s hotel assets from its largest shareholder in a reverse takeover (RTO) deal valued at RM425.9mil.
KUALA LUMPUR: Datuk Seri Farouk Abdullah, who emerged as a substantial shareholder in Bio Osmo Bhd in April last year, is injecting his Impiana hotel business in Malaysia into the loss making company in a bid to turn it around.
At 11am, the benchmark FTSE Bursa Malaysia KLCI (FBM KLCI) stood at 1,736.36, down 7.72 points from yesterday's close of 1,744.08. — Reuters picKUALA LUMPUR, April 13 — Bursa Malaysia continued to trade lower at mid-morning weighed by losses in selected heavyweights led by CIMB and Axiata.
At 9.37am, the benchmark FTSE Bursa Malaysia KLCI (FBM KLCI) stood at 1,738.41, down 5.67 points from yesterday’s close of 1,744.08. — Reuters picKUALA LUMPUR, April 13 — Bursa Malaysia opened lower today on profit taking after yesterday’s strong gains.
An investor monitors share market prices at a brokerage firm in Kuala Lumpur. — Reuters picKUALA LUMPUR, April 6 ― Bursa Malaysia ended lower today in line with regional markets as sentiment turned cautious over US Federal Reserve's plan to cut its US$4.5 trillion (US$1 = RM4.43) balance sheet later this year.
An investor monitors share market prices at a brokerage firm in Kuala Lumpur, Malaysia, August 24, 2015. — Reuters picKUALA LUMPUR, April 6 — Bursa Malaysia ended the morning session lower today, as sentiment turned cautious on the US Federal Reserve’s (Fed) plan, to trim its US$4.5 trillion balance sheet later this year.
An investor monitors share market prices at a brokerage firm in Kuala Lumpur, Malaysia, August 24, 2015. — Reuters picKUALA LUMPUR, April 6 — Bursa Malaysia turned lower at mid-morning today on lack of catalyst and in line with the weaker Wall Street performance overnight.
An investor monitors share market prices at a brokerage firm in Kuala Lumpur, Malaysia, August 24, 2015. — Reuters picKUALA LUMPUR, April 6 — Bursa Malaysia opened mixed with the composite index in the negative territory in line with Wall Street’s weaker performance, overnight.
KUALA LUMPUR, March 31 — Bursa Malaysia ended the morning session lower today due to selling activities mostly in bluechips and penny stocks, dealers said.
An investor monitors share market prices at a brokerage firm in Kuala Lumpur, Malaysia, August 24, 2015. — Reuters picKUALA LUMPUR, March 15 — Bursa Malaysia opened lower today on lack of demand for local stocks.
KUALA LUMPUR, March 14 — Bursa Malaysia finished slightly higher today on mild buying interests, dealers said.
KUALA LUMPUR, Feb 17 — Bursa Malaysia extended yesterday's losses on continued selling pressure to open lower this morning in line with the softer overnight tone of US and European stock markets.
2018-05-19 - Asif
OVERVIEW Sangamo BioSciences is a clinical stage biotechnology company focused on translating ground-breaking science into genomic therapies that transform patients’ lives using its industry-leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy. Sangamo BioSciences is a leader in the research and development of zinc finger proteins, or ZFPs, a naturally occurring class of proteins found in humans. Sangamo BioSciences has used its knowledge and expertise to develop a proprietary technology platform in both genome editing and gene regulation. ZFPs can be engineered to make zinc finger nucleases, or ZFNs, proteins that can be used to specifically modify DNA sequences by adding or knocking out specific genes, or genome editing, and ZFP transcription factors or ZFP TFs, proteins that can be used to increase or decrease gene expression, or gene regulation. In the process of developing this platform, Sangamo BioSciences has accrued signific...
2018-05-19 - Asif
Business Overview The company provide high quality information technology, or IT, services and solutions including a range of technology platforms focusing on big data, business intelligence, and consumer-centric technology. More recently, to provide greater value to stockholders, the Company has sought to expand its business primarily through acquisitions that leverage its capabilities and expertise. As of March 31, 2018, the Company owned 81.2%, and as of the date of this report the Company owns 91.8%, of the outstanding shares of MoviePass (excluding outstanding MoviePass options and warrants). MoviePass is the premiere movie theater subscription service in the United States which provides its subscribers the ability to view up to one new movie title per day for one monthly subscription price. The company's more than 2 million subscribers have access to see films in over 91% of U.S movie theaters. By the end of April 2018, the company implemented certain measures ...
2018-05-17 - Asif
Overview Biostage is a biotechnology company developing bioengineered organ implants based on its novel CellframeTM technology. The company's Cellframe technology is comprised of a biocompatible scaffold that is seeded with the recipient’s own stem cells. This technology is being developed to treat life-threatening conditions of the esophagus, trachea or bronchus with the objective of dramatically improving the treatment paradigm for those patients. The company believe that its Cellframe technology will provide surgeons with new ways to address damage to the esophagus, bronchus, and trachea due to congenital abnormalities, cancer, infection or trauma. Products being developed based on its Cellframe technology for those indications are called CellspanTM products. The company announced favorable preliminary pre-clinical results of large-animal studies for the esophagus, trachea and bronchus in November 2015. Since then, the Cellspan esophageal implant product candidates hav...